Investigational new drugsHumansDrug SynergismCell LineTumorCell Proliferation
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells.
Arianna Bandini, Letizia Biso, Cristina Viaggi, Carla Pardini, Paola Orlandi, Marco Carli, Marta Banchi, Luca Filippi, Guido Bocci, Marco Scarselli
Published: 202510.1007/s10637-025-01587-8
Abstract
β3-adrenergic receptors (β3-ARs) are increasingly recognized as modulators of tumor progression and treatment resistance across multiple cancer types. SR59230A, a β3-AR antagonist, has shown preclinical antitumor activity through mechanisms involving…
Preview only. Read the full abstract at the source